AHR and myeloid sarcoma: In this context, the AHR agonist laquinimod showed promising preclinical results (98, 99), but clinical trials (NCT02284568, NCT01707992) (100, 101) investigating its use in MS patients did not reach their primary endpoints, with higher doses characterized by high toxicity.